Skip to main content

Veraxa Biotech AG

corporate_fare Company Profile

Veraxa Biotech AG

VRXA·NASDAQ·Life Sciences·CIK 0002079109

Veraxa Biotech Holding AG operates in the biotechnology sector, focusing on microfluidics-based antibody screening technology. The company's business activities commenced upon the closing of a business combination where Veraxa Biotech AG merged into PubCo, with PubCo as the surviving entity. Veraxa Biotech Holding AG holds intellectual property, including patents relevant to its Hitmaster and microfluidics-based antibody screening technology. One key patent, titled "MICROFLUIDIC DROPLET DETECTION AND SORTING," describes a microfluidic system designed to detect and sort droplets containing particles labeled with detectable markers. This system identifies droplets based on the presence and intensity of these markers and directs them into different channels for sorting. The method also supports quantitative binding assays and high-throughput applications such as single-cell analysis, drug screening, and diagnostics. This patent was filed on 4/29/16 and is granted in Canada (CA2984045), China (CN107810413), Europe (EP3289362, with opposition rejected and in appeal), Hong Kong (HK1251660), Israel (IL255260), India (IN364123), Japan (JP6851982), and the USA (US10710078), with an expiration date of 4/29/36 in all these regions. The European patent is validated in AT, BE, CH, CZ, DE, DK, ES, FR, GB, IE, IT, LU, NL, PT, and SE. Another patent, titled "MICROFLUIDIC ANALYSIS OF LIGAND INDUCED CELL EXPRESSION," is also relevant for Veraxa's Hitmaster and microfluidics-based antibody screening technology. This patent describes a microfluidic system that analyzes cellular responses to ligands at the single-cell level. It encapsulates individual cells in microdroplets and exposes them to specific ligands to detect and quantify changes in gene expression. This method enables high-throughput, quantitative binding assays, facilitating applications in drug discovery and cellular biology research.

Veraxa Biotech AG (NASDAQ:VRXA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for VRXA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for VRXA spans 6-K, 424B5, F-1, 20-F.

Recent high-impact activity:

  • Veraxa Auditor BDO Resigns; KPMG Proposed at 10 December EGM
  • Veraxa Biotech Reports First In Vivo Proof-of-Concept for BiTAC-ADC Platform
  • Veraxa Registers 25M Shares for Lincoln Park Equity Line Resale
  • Veraxa Biotech Files F-1 to Register 140M+ Shares for Resale and Warrant Exercise, Unlocking Massive Overhang
  • Veraxa Biotech Registers 25M Shares for Lincoln Park Resale Under $50M Equity Line

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 91,222 shares in VRXA as of the October 30, 2026 settlement, a 15.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 29.5% of VRXA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)91,222 shares as of October 30, 2026
Change vs prior period▼ 15.0%
Days to cover1.00 at avg daily volume of 164,496
Daily short volume (FINRA facilities)29.5% of 45,546 shares on November 20, 2026
5-day average short volume20.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for VRXA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-10.

2 shelf registrations

Equity Line Registration Effective · Dilution Overhang

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

VRXA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with V →
$1.02 -0.97% today
52-week range · as of 2026-11-19 $0.90 – $27.36
Market cap
$153.64M
Volume
114.6K (0.7× avg)
3-mo avg 168.6K
Live data · 2026-11-22 12:24 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VRXA - Latest Insights

VRXA
Nov 19, 2026, 4:10 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $1.02 info
Change: -$0.010 (-0.97%) info
Market Cap: $153.642M info
VRXA
Oct 13, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $1.02 info
Change: -$0.210 (-17%) info
Market Cap: $153.642M info
VRXA
Aug 10, 2026, 5:20 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.83
Real-time Price: $1.02 info
Change: -$0.810 (-44%) info
Market Cap: $153.642M info
VRXA
Jul 31, 2026, 5:13 PM EDT
Filing Type: F-1
Importance Score:
8
Price at Filing: $1.82
Real-time Price: $1.02 info
Change: -$0.800 (-44%) info
Market Cap: $153.642M info
VRXA
Jul 31, 2026, 5:13 PM EDT
Filing Type: F-1
Importance Score:
7
Price at Filing: $1.82
Real-time Price: $1.02 info
Change: -$0.800 (-44%) info
Market Cap: $153.642M info
VRXA
Jul 27, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.97
Real-time Price: $1.02 info
Change: -$0.950 (-48%) info
Market Cap: $153.642M info
VRXA
Jul 27, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $1.02 info
Change: -$0.780 (-43%) info
Market Cap: $153.642M info
VRXA
Jul 23, 2026, 12:22 PM EDT
Source: FinanceWire
Importance Score:
7
Price at Filing: $1.87
Real-time Price: $1.02 info
Change: -$0.850 (-45%) info
Market Cap: $153.642M info
VRXA
Jul 20, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.23
Real-time Price: $1.02 info
Change: -$1.21 (-54%) info
Market Cap: $153.642M info
VRXA
Jul 13, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.02 info
Change: -$1.16 (-53%) info
Market Cap: $153.642M info
VRXA
Jul 07, 2026, 12:07 PM EDT
Source: FinanceWire
Importance Score:
7
Price at Filing: $2.70
Real-time Price: $1.02 info
Change: -$1.68 (-62%) info
Market Cap: $153.642M info
VRXA
Jul 06, 2026, 12:37 PM EDT
Source: FinanceWire
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $1.02 info
Change: -$1.09 (-52%) info
Market Cap: $153.642M info
VRXA
Jun 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.92
Real-time Price: $1.02 info
Change: -$1.90 (-65%) info
Market Cap: $153.642M info
VRXA
Jun 18, 2026, 5:20 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.25
Real-time Price: $1.02 info
Change: -$3.23 (-76%) info
Market Cap: $153.642M info
VRXA
Jun 16, 2026, 4:30 PM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $9.20
Real-time Price: $1.02 info
Change: -$8.18 (-89%) info
Market Cap: $153.642M info
VRXA
Jun 16, 2026, 3:54 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $10.73
Real-time Price: $1.02 info
Change: -$9.71 (-90%) info
Market Cap: $153.642M info
VRXA
Jun 16, 2026, 3:39 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $10.64
Real-time Price: $1.02 info
Change: -$9.62 (-90%) info
Market Cap: $153.642M info
VRXA
Jun 15, 2026, 3:46 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $23.05
Real-time Price: $1.02 info
Change: -$22.03 (-96%) info
Market Cap: $153.642M info
VRXA
Jun 15, 2026, 3:23 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $22.18
Real-time Price: $1.02 info
Change: -$21.16 (-95%) info
Market Cap: $153.642M info
VRXA
Jun 10, 2026, 6:04 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $24.79
Real-time Price: $1.02 info
Change: -$23.77 (-96%) info
Market Cap: $153.642M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets